42
Participants
Start Date
October 22, 2023
Primary Completion Date
July 23, 2026
Study Completion Date
November 5, 2026
Spesolimab
Spesolimab intravenous (i.v.) infusion
National Taiwan University Hospital, Taipei
Chang Gung Memorial Hospital Linkou, Taoyuan District
Hedi Chaker Hospital, Department of Dermatology, Sfax
Cliniques Universitaires Saint-Luc, Brussels
Westmead Hospital, Westmead
Liverpool Hospital, Liverpool
Farhat Hached Hospital, Sousse
Nelson Mandela Academic Clinical Research Unit (NeMACRU), Mthatha, Eastern Cape
Hospital Pulau Pinang-Pulau Pinang-21953, Georgetown Pulau Pinang
ASST degli Spedali Civili di Brescia, Brescia
Hospital Universitario Ramon Y Cajal, Madrid
HOP Trousseau, Chambray-lès-Tours
Srinagarind Hospital, Khon Kaen
Sunway Medical Centre, Selangor Darul Ehsan
Maharat Nakhonchiangmai Hospital, Muang Chiang Mai
Hospital Kuala Lumpur, Kuala Lumpur
Red River Research Partners, LLC, Fargo
Universitätsklinikum Frankfurt, Frankfurt am Main
Hospital Putrajaya, Putrajaya
Hospital Selayang, Batu Caves
HOP Saint-Louis, Paris
Hospital Sultanah Aminah, Johor Bahru
Klinikum der Universität München AÖR, München
Hospital Sultan Ismail, Johor Bahru
University of California Irvine, Irvine
National University Hospital-Singapore-42005, Singapore
Shanghai Skin Disease Hospital, Shanghai
Shanghai Tenth People's Hospital, Shanghai
SP medical college and associated group of hospitals, Bikaner
Nkp Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur
Southern Medical University Dermatology Hospital, Guangzhou
Hospital Universitario Evangelico Mackenzie, Curitiba
Faculdade de Medicina do ABC, Santo André
Seoul National University Hospital, Seoul
Hospital Universitari Vall D Hebron, Barcelona
Lead Sponsor
Boehringer Ingelheim
INDUSTRY